3 edition of Symposium on the Clinical Significance of Quality of Life Measures in Cancer Patients (Mayo Clinic Proceedings Symposiums) found in the catalog.
Symposium on the Clinical Significance of Quality of Life Measures in Cancer Patients (Mayo Clinic Proceedings Symposiums)
2002 by Mayo Foundation for Medical Education .
Written in English
|The Physical Object|
QUALITY OF LIFE OF CANCER PATIENTS DURING THE CHEMOTHERAPY PERIOD Thalyta Cristina Mansano-Schlosser¹, Maria Filomena Ceolim² 1 Doctoral student of the Nursing Department Graduate Program at the College of Medical Sciences (FCM) at Campinas University (Unicamp). São Paulo, Brazil. E-mail: [email protected] 2 Ph.D. in Nursing. Quality of life in cancer patients - an hypothesis K C Caiman Department of Oncology, University of Glasgow Author's abstract Quality of life is a difficult concept to define and to measure. An hypothesis is proposed which suggests that the quality of life measures the difference, or the gap, at a particular period of time between the hopes and. A recent editorial published in the Journal of Clinical Oncology pointed out that it is ‘disappointing’ that despite the fact that thousands of patients have been enrolled in cancer clinical trials with a HRQOL component, ‘there are relatively few examples of formal quality-of-life measurement that have influenced individual patient Cited by: Cancer of the prostate is the most common cancer in men (excluding nonmelanomatous skin cancer) with approximately new cases expected to be diagnosed during (1).For patients with metastatic prostate cancer, treatment is primarily palliative (2).Endocrine manipulations remain the standard approach, and these manipulations rely Cited by:
B-NR-NEL 4800 Lo:
Practical pricing for results
China in convulsion
Receptions to training schools in Northern Ireland, 1994 & 1995.
From Ichcanzihoo to Mérida
Honoré de Balzac, his life and writings
Interdisciplinary Teaching in the Middle Grades
A digest of the treaty, laws, and regulations governing the admission of Chinese, their residence in and transit through the United States and its insular possessions.
Water-quality assessment of the Ozark Plateaus study unit, Arkansas, Kansas, Missouri, and Oklahoma
Spades and feathers
Optical aberration coefficients
Little Instruction Book, Rich Family
The purpose of the Symposium in the Clinical Significance of Quality of Life Measures in Cancer Patients was to delineate in simple language the degree of consensus that existed regarding clinical significance.
Symposium on Quality of Life in Cancer Patients Assessing Clinical Significance in Measuring Oncology Patient Quality of Life: Introduction to the Symposium, Content Overview, and Definition of Terms Author links open overlay panel Jeff A.
Sloan PhD a David Cella PhD c Marlene H. Frost PhD, RN b Gordon H. Guyatt MD d Mirjam A.G. Sprangers PhD Cited by: The entire Symposium on the Clinical Significance of Quality-of-Life Measures in Cancer Patients will be available for purchase as a bound booklet Cited by: symposium on quality of life in cancer patients Assessing the Clinical Significance of Single Items Relative to Summated Scores Author links open overlay panel Jeff A.
Sloan PhD a Neil Aaronson PhD b Joseph C. Cappelleri PhD, MPH c Diane L. Fairclough DRPH d Claudette Varricchio DSN, RN e THE CLINICAL SIGNIFICANCE CONSENSUS MEETING GROUPCited by: Patient, Clinician, and Population Perspectives on Determining the Clinical Significance of Quality-of-Life Scores.
Despite the success of screening and treatment of major cancers in the United States, cancer remains a chronic condition dominated by symptoms and treatment-related adverse by: The Clinical Significance Consensus Meeting Group of the Symposium on the Clinical Significance of Quality-of-Life Measures in Cancer Patients produced 6 articles regarding the clinical significance of quality of life (QOL) assessments in oncology.
The 6 articles deal with the methods used to date: group-vs-individual clinical significance Cited by: The Clinical Significance Consensus Meeting Group of the Symposium on the Clinical Significance of Quality-of-Life Measures in Cancer Patients produced 6 articles regarding the clinical significance of quality of life (QOL) assessments in by: ASCO GU Comparative Quality of Life in Patients Randomized Contemporaneously to Docetaxel or Abiraterone In the STAMPEDE Trial San Francisco, CA USA () In recent years, both docetaxel and abiraterone have been shown to improve overall survival when added to standard androgen deprivation therapy (ADT) for men with metastatic hormone.
Figure 1 - statistical significance and clinical irrelevance. The effect is the estimate of the impact for the treatment being tested. Many primary outcomes in cancer trials use time to event data looking at overall survival and progression-free survival.
Time to event data is challenging because of incomplete data leading to censoring. A QOL instrument was developed to measure the specific concerns of long term cancer survivors. The QOL-CS is based on previous versions of the QOL instrument developed by researchers at the City of Hope National Medical Centre (Grant, Padilla, and Ferrell).
This instrument was revised over a one year pilot by Hassey-Dow and Ferrell. The revised Cited by: The original six articles were presented at the Symposium on Clinical Significance of Quality of Life Measures in Cancer Patients at the Mayo.
Objective: This report extracts important considerations for determining and applying clinically significant differences in quality of life (QOL) measures from six published articles written by 30 international experts in the field of QOL assessment and original six articles were presented at the Symposium on Clinical Significance of Quality of Life Measures in Cancer Patients Cited by: The entire Symposium on the Clinical Significance of Quality-of-Life Measures in Cancer Patients will be available for purchase as a bound booklet from the Proceedings Editorial Office at a later date.
A complete list of other Clinical Significance Consensus Meeting Group contributors to this article appears at the end of the by: The objective of this study is to describe the quality of life (QoL) in cancer patients with solid tumors and at different chemotherapy (CT) cycles.
A total of cancer patients were included. With some modification, the European Organization for Research and Treatment. Following the development of reliable and valid self-report questionnaires, health-related quality of life has been assessed in tens of thousands of patients and a wide variety of cancers.
This review is based on a selection of data published in the last decade and is intended primarily for healthcare by: Cancer can produce many different symptoms, some subtle and some not at all subtle. An increasingly important issue in oncology is to evaluate quality of life (QoL) in cancer patients.
The cancer-specific QoL is related to all stages of this by: The Clinical Significance Consensus Meeting Group of the Symposium on the Clinical Significance of Quality-of-Life Measures in Cancer Patients produced 6 articles regarding the clinical significance of quality of life (QOL) assessments in oncology.
Having a potentially life-threatening disease like cancer often leads people to examine their lives and look for meaning. In fact, this search for meaning may be the aspect of cancer that most often has a positive influence on life. The fear of death that affects most people when they are diagnosed with cancer, often leads us to think about.
Among the most widely used instruments to assess quality of life (QOL) in patients with cancer are the European Organization for Research and Treatment of Cancer core questionnaire (EORTC QLQ-C30) and the Functional Assessment of Chronic Illness Therapy, cancer instrument (FACT-G).
This study compared these approaches in patients who had undergone esophagectomy for by: Introduction It is our pleasure to invite you to the 5th EORTC Quality of Life in Cancer Clinical Trials Conference which will be held in This event will give participants the opportunity to learn about the latest topics in quality of life (QOL) and patient reported outcomes research.
The two-day conference aims to. and in global quality of life (global QL) and the QLQ-C30 were completed by patients who received chemother- apy for either breast cancer or small-cell lung cancerFile Size: KB.
The most recent studies supplemented their assessments with site-specific questionnaires. Overall, 59 different instruments have been used to measure quality of life in cancer patients [Additional file 1]. The EORTC QLQ-C30 was found to be the most widely used cancer-specific instrument, and as the tables in this review show, the questionnaire Cited by: Introduction As patient assessment of health-related quality of life (HRQOL) in cancer clinical trials has increased over the years, so has the need to attach meaningful interpretations to differences in HRQOL scores between groups and changes within groups.
Determining what represents a minimally important difference (MID) in HRQOL scores is useful to clinicians, patients Cited by: Quality of Life in Cancer Patients undergoing Chemotherapy.
quality of life in breast cancer patients Saeed a printable copy PDF file of the complete article K, or click on a page image below to browse page by page.
Aaronson NK. Methodologic issues in assessing the quality of life of cancer patients. Cancer. Feb 1; 67 (3 Suppl)– [Au E, Loprinzi CL, Dhodapkar M, Nelson T, Novotny P, Hammack J, O'Fallon J. Regular use of a verbal pain scale improves the understanding of oncology inpatient pain by: Cancer and chemoradiotherapy have a significant adverse impact on the quality of life (QOL) of cancer patients.
With the advent of new and more effective cancer therapies, patients with cancer are surviving longer than in the past. This has led to increased importance for maintaining good QOL in cancer by: 1. The PIQoL-AD has been used in several trials assessing quality of life (QoL) in parents of children with atopic dermatitis (AD), treated with pimecrolimus cream 1%.
Secondary analysis of data from four trials (n = ) was undertaken to help interpret the meaningfulness (significance) of the QoL results. A combination of anchor-based and distribution-based Cited by: Maximizing quality of life for cancer patients means that cancer treatment is focused on treating both the disease and the person.
This form of treatment is also called palliative care. According to National Cancer Institute, the goal of palliative care is to prevent or treat, as early as possible, the symptoms and side effects of the disease. A 'read' is counted each time someone views a publication summary (such as the title, abstract, and list of authors), clicks on a figure, or views or downloads the full-text.
In this pooled analysis, the authors examined correlations between single-item and multiple-item quality of life (QOL) measures and assessed the agreement between clinically significant changes in QOL and patient-reported adverse events (AE).
METHODS. Data from 6 lung cancer clinical trials that involved patients were by: Improving the Quality of Life for Lung Cancer Patients Draft2V5 – December 2, CC 2 Quality of Life and Patient Reported Outcomes: Relation to Major Clinical Outcomes Definitions of quality of life (QOL) and the individual components of which it consists for lung cancer patients may always be variable to an extent.
Cancer research still has much ground to cover, but cancer treatments are extending life. According to the American Cancer Society, the average five-year survival rate for all cancer patients has Author: Joe Dustin.
Developing Quality Indicators for Cancer End-of-Life Care Proceedings From a National Symposium Article in Cancer (17) July with 77 Reads How we measure.
It was more than 30 years ago that the first efforts to incorporate quality-of-life (QOL) measurements into cancer treatment trials began in studies of women with advanced breast cancer (1).In that study, the investigators used an ad hoc instrument with linear analog scales to focus on the common side effects of chemotherapy that was being given to women with advanced metastatic breast cancer Cited by: Symposium on Quality of Life in Cancer Patients Assessing Clinical Significance in Measuring Oncology Patient Quality of Life: Introduction to the Symposium, Content Overview, and Definition of Terms Jeff A.
Sloan, David Cella, Marlene H. Frost, Gordon H. Guyatt, Mirjam A.G. Sprangers, Tara Symonds, Clinical Significance Consensus Meeting Group. Movsas B, Hu C, Sloan J, et al. Quality of life analysis of a radiation dose–escalation study of patients with non–small-cell lung cancer: a secondary analysis of the Radiation Therapy Oncology Group randomized clinical Cited by: 1.
Measuring the effects of anemia treatment with quality of life tools is a fine example of the importance of these tools to gauge the impact and clinical significance of interventions. It is, therefore, both timely and relevant that we dedicate our fifth symposium to the management of anemia in patients with : N.
Simon Tchekmedyian, Facp, David F. Cella, John A. Glaspy. new patients with bladder cancer and/or are scheduled for radical cystectomy and urinary diversion Behavioral: Quality Of Life questionnaires All patients who agree to participate will be interviewed using a baseline idiographic quality of life assessment prior to surgery and at approximately 6, 12, 18 and 24 months postoperatively.
The EORTC measures QLQ-C30 and -CX24 have also been used in the study of QOL in cervical cancer patients. InGreimel et al. published the data on the development and validation of this tool.
Measuring quality of life in breast cancer patients is of importance in assessing treatment outcomes. This study examined the impact of breast cancer diagnosis and its treatment on quality of life of women with breast cancer.
This was a prospective study of quality of life in breast cancer patients. Quality of life was measured using the European Organization for Cited by:. Initial results of CALGB (Alliance): A randomized phase II trial of PET scan-directed combined modality therapy for esophageal cancer.
Goodman et al. Nivolumab (ONO/BMS) as salvage treatment after second or later-line chemotherapy for advanced gastric or gastro-esophageal junction.Quality of life (QoL) in patients with non-small cell lung cancer is reviewed along with interpretation of results from clinical trials and new technologies to measure the QoL in clinical.
Most patients with colorectal cancer survive at least five years after diagnosis , making health-related quality of life (HRQL) an important outcome for these t-reported outcomes including HRQL have been used in conjunction with traditional clinical outcomes, such as treatment response rates and disease-free survival, to assess treatment efficacy in randomized clinical Cited by: